Bridgebio Oncology Therapeut (BBOT) 13F Holders & Ownership Data (65 Funds, Q2 2026)

BBOT ranks #5527 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

BBOT is a top-conviction position for Omega Fund Management, LLC — at 13.5% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in BBOT belongs to Cormorant Asset Management, LP, but the position matters far more to Omega Fund Management, LLC, who has 13.5% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

BBOT is down 4.6% today, but institutions show net buying of $38.0M this quarter — a divergence between today's price move and the underlying institutional flow.

BBOT reported a net loss of $134.0M in its latest fiscal year.

• Not yet profitable — net loss of $134.0M in the latest fiscal year
• Net income declined year over year, from -$74.3M to -$134.0M
• Operating cash flow was negative, using $113.9M in cash
• Current ratio of 12.34x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.09x equity — within a conventional range